Researchers reported results for the secondary end point overall survival. Postmenopausal women with ER+/HER2– advanced breast cancer (ABC) without previous systemic therapy for ABC were randomly assigned 2:1 to palbociclib plus letrozole or placebo plus letrozole.
[Journal Of Clinical Oncology]
